Wayne Koberstein
-
State Of The Orphan Space
3/1/2024
Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing practices.
-
Companies To Watch: Antiva Biosciences
2/27/2024
Antiva Biosciences is exploring a local and global opportunity with a topically administered HPV treatment.
-
Companies to Watch: Promontory Therapeutics
2/1/2024
A novel small molecule developer aims to shake up the solid tumor treatment landscape.
-
Empress Builds Base for Small-Molecule Innovation
2/1/2024
Empress, launched by Flagship Pioneering, aims to harness AI and evolutionary biology to design the next generation of small molecule therapies.
-
Neurvati Maps Path To Neuroscience Approvals
1/1/2024
Can a nested financial model help bring the next generation of neuroscience treatments to patients?
-
Companies To Watch: KeifeRx
1/1/2024
Founded in late 2019, KeifeRx is repurposing oncology drugs for neurodegenerative disorders.
-
Biopharma’s Eminent Challenges In 2024 — Inside & Out
12/1/2023
A baker’s dozen of biopharma CEOs answer a call to prioritize and describe challenges they expect to face in the coming year.
-
Heading Back Home To The Heart
11/1/2023
Cardior Pharmaceuticals, led by CEO and cofounder Claudia Ulbrich, is developing what may be a much broader approach to heart failure, one that seeks to restore the diseased heart to its natural healthy state.
-
Companies To Watch: Freya Biosciences
11/1/2023
Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.
-
Companies To Watch: Spruce Biosciences
10/2/2023
Spruce Biosciences is currently in mid-to-late stage clinical development of new agents to treat rare endocrine disorders.